| Home | Contact us | Search
 

One off donation
Regular donation


Kidney Cancer in the 2010 UK Election News >>

NICE reject Bevacizumab, sorafenib and temsirolimus >>

Press archive - 2009 >>

Press archive - 2010 >>

Press archive - 2008 >>

Press archive - 2007 >>

Press archive - 2006 >>


James Whale Fund for Kidney Cancer welcomes NICE approval of drug in the fight against kidney cancer >>
24 December 2010


The James Whale Fund for Kidney Cancer - Curry & A Quiz Final Quarter 2010 >>
20 October 2010


The James Whale Fund for Kidney Cancer Cardiff Half Marathon Team 2010 >>
17 October 2010


Pazopanib (proprietary name Votrient) >>
14 October 2010


Cancer: the revolution has begun >>
2 October 2010


First conference of The International Kidney Cancer Coalition gives voice to national patient groups >>
27 September 2010


Charity launches first renal cancer nurse training programme >>
24 September 2010


Wellesbourne Calendar Girls bare all for the James Whale Fund >>
23 September 2010


62-mile ride for kidney research! >>
22 September 2010


The Cancer Reform Strategy >>
3 August 2010


Launch of Britain's Biggest Curry Party >>
24 June 2010


Riding from Arch to Arc in aid of kidney cancer >>
24 June 2010


James Whale, Founder & Chairman of the UK's leading klidney cancer charity welcomes The Kidney Cancer Association to British shores! >>
13 April 2010


Response to Conservative Party news on availability of cancer drugs >>
4 April 2010


Drug proved to prolong kidney cancer patients' lives deemed too expensive by NICE >>
9 February 2010


NICE consults on preliminary decision not to recommend everolimus for advanced renal cell carcinoma >>
9 February 2010


Novartis Oncology concerned by initial NICE decision to deny advanced kidney cancer patients effective treatment with Afinitor® (everolimus) >>
9 February 2010


Cancer care plans could cut costs >>
27 January 2010


Technology Appraisal at NICE - EVEROLIMUS ( AFINITOR) - by Bill Savage >>
13 January 2010


News articles relating to N.I.C.E. decision to deny Afinitor >>
9 February 2010


Response to Conservative Party news on availability of cancer drugs

Rose Woodward, herself a survivor of kidney cancer and Patient Advocate for the James Whale Fund for Kidney Cancer said “On behalf of the James Whale Fund for kidney Cancer and my fellow kidney cancer patients, we welcome the news today that Conservative Party will set up a Fund to enable patients suffering from rarer cancers to get the cancer drugs they desperately need.

Over the past 4 years, on behalf of terminally cancer patients from all over the Country, we have been pleading in front of jury’s of PCT administrators to allow patients to have proven, innovative cancer drugs that Clinicians want to prescribe. By anyone’s standards it is cruel and callous to refuse to treat vulnerable patients who are already having to cope with a diagnosis of a serious cancer.

At the James Whale Fund we are passionate believers in the NHS and universal care. We welcome the day when it is the Doctor who will decide what drugs he will prescribe for his patient not an administrator sitting behind a desk far away from the Hospital.

N I C E (National Institute of Health & Clinical Excellence) denies drugs on the basis of cost, but Oncologists want to prescribe drugs on the basis of clinical effectiveness and the needs of their patients.

Cancer patients need to know the NHS will be there for them when they most need it and at the moment they are being let down. The NHS must stop saying to cancer patients “You are too expensive for us to keep you alive.”


Rose Woodward.

Patient Advocate for the James Whale Fund for Kidney Cancer.

Founder of the Kidney Cancer Support Network